Home / LOBEF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does LOBEF make money? Does LOBEF have pricing power? What's the Earnings Whisper? Will LOBEF profit more as the business scales? What is LOBEF's management track record? Is LOBEF's current price justified?

Lobe Sciences Ltd.

$0.05 +$0.02 (+48.06%)

OTC · 14 Sep 2026 20:00 UTC

Previous Close

$0.06

Day Range

$0.05$0.06

Year Range

$0$0.06

Market Cap

15.14M

AVG Volume

84.75K

Trailing/Forward PE

-3.4/-

PEG ratio

-0.08

Dividend Yield

Next Earnings Date

2026-12-28

Primary Exchange

Other OTC

Revenue (CAD)

LOBEF Revenue (CAD) by year
Period	Revenue (CAD)
2025	0
2024	204.31K
2023	840.53K
2022	0
2021	180.62K
2020	884.84K
2019	773.79K
2018	0
2017	0
2016	0

Net Income (CAD)

LOBEF Net Income (CAD) by year
Period	Net Income (CAD)
2025	-4.43M
2024	-4.42M
2023	-4.71M
2022	-12.25M
2021	-9.66M
2020	-3.44M
2019	-41.95K
2018	-56.05K
2017	-56.02K
2016	-156.55K

Operating Income (CAD)

LOBEF Operating Income (CAD) by year
Period	Operating Income (CAD)
2025	-4.18M
2024	56.92K
2023	-2.33M
2022	-4.12M
2021	-6.28M
2020	-3.45M
2019	-1.63M
2018	-56.08K
2017	-45.81K
2016	-47.28K

EBITDA (CAD)

LOBEF EBITDA (CAD) by year
Period	EBITDA (CAD)
2025	-4.23M
2024	-4.12M
2023	-4.42M
2022	-4.3M
2021	-6.02M
2020	-2.92M
2019	717.78K
2018	-42.32K
2017	-45.81K
2016	-47.28K

Cash Flows (CAD)

LOBEF Cash Flows (CAD) by year
Period	Cash Flows (CAD)
2025	-1.42M
2024	-462.29K
2023	-1.72M
2022	-2.73M
2021	-5.04M
2020	-1.22M
2019	-1.35M
2018	-38.68K
2017	-44.03K
2016	-46.78K

EPS (CAD)

LOBEF EPS (CAD) by year
Period	EPS (CAD)
2025	-0.02
2024	-0.04
2023	-0.05
2022	-0.32
2021	-0.24
2020	-0.26
2019	-0.07
2018	-0.08
2017	-0.08
2016	-0.23

Expenses (CAD)

LOBEF Expenses (CAD) by year
Period	Expenses (CAD)
2025	3.3M
2024	2.2M
2023	4.78M
2022	4.11M
2021	6.32M
2020	2.87M
2019	1.9M
2018	56.08K
2017	45.81K
2016	47.28K

Cash & Debt (CAD)

LOBEF Cash & Debt (CAD) by year
Period	Cash & Debt (CAD)
2025	7.54M
2024	237.77K
2023	220.66K
2022	907.54K
2021	7.43M
2020	172.11K
2019	512.78K
2018	4.03K
2017	42.96K
2016	39.8K

Debt ratios

LOBEF Debt ratios by year
Period	Debt ratios
2025	0.43
2024	-0.08
2023	-0.01
2022	0.07
2021	0.9
2020	-0.06
2019	-0.88
2018	0.02

Margins

LOBEF Margins by year
Period	Margins
2024	63.96%
2023	91.94%
2021	100%
2020	98.76%
2019	57.21%

Return on Capital

LOBEF Return on Capital by year
Period	Return on Capital
2025	-90.58%
2024	141.93%
2023	2939.54%
2022	-2749.44%
2021	-85.53%
2020	-28.46%
2019	-0.68%
2018	435.19%
2017	-128.99%
2016	-299.62%

Shares Outstanding

LOBEF Shares Outstanding by year
Period	Shares Outstanding
2025	222.21M
2024	158.78M
2023	134.23M
2022	38.44M
2021	38.44M
2020	15.7M
2019	9.09M
2018	741.67K
2017	741.67K
2016	700K

Book Value Per Share (CAD)

LOBEF Book Value Per Share (CAD) by year
Period	Book Value Per Share (CAD)
2025	0.02
2024	-0.02
2023	-0
2022	0.01
2021	0.29
2020	0.77
2019	0.68
2018	-0.02
2017	0.06
2016	0.07

Total Assets (CAD)

LOBEF Total Assets (CAD) by year
Period	Total Assets (CAD)
2025	7.58M
2024	258.57K
2023	2.3M
2022	1.75M
2021	12.1M
2020	12.97M
2019	6.72M
2018	4.78K
2017	43.43K
2016	52.25K

Free Cash Flow Yield

LOBEF Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-18.23%
Sep 26	-16.67%
Sep 26	-16.31%
Aug 26	-14.93%
Aug 26	-14.76%
Aug 26	-17.71%
Aug 26	-16.14%
Jul 26	-16.89%
Jul 26	-12.66%
Jul 26	-13.73%
Jul 26	-11.71%
Jul 26	-12.34%
Jun 26	-13.96%
Jun 26	-14.12%
Jun 26	-11.38%
Jun 26	-11.46%
May 26	-12.19%
May 26	-5.27%
May 26	-4.71%
May 26	-4.57%
May 26	-5.36%
Apr 26	-5.16%
Apr 26	-8.06%
Apr 26	-8.94%
Apr 26	-9.22%
Mar 26	-8.28%
Mar 26	-9.66%
Mar 26	-9.56%
Mar 26	-105.13%
Feb 26	-10.31%
Feb 26	-9.76%
Feb 26	-12.94%
Feb 26	-11.24%
Jan 26	-10.41%
Jan 26	-12.15%
Jan 26	-8.76%
Jan 26	-9.65%
Jan 26	-12.9%
Dec 25	-13.74%
Dec 25	-14.01%
Dec 25	-14.78%
Dec 25	-15.7%
Nov 25	-109.57%
Nov 25	-17.04%
Nov 25	-12.74%
Nov 25	-127.16%
Oct 25	-11.29%
Oct 25	-12.26%
Oct 25	-12.74%
Oct 25	-10.35%
Oct 25	-10.25%
Sep 25	-10.5%
Sep 25	-10.37%
Sep 25	-11.35%
Sep 25	-10.34%
Aug 25	-10.55%
Aug 25	-9.03%
Aug 25	-8.9%
Aug 25	-10.17%
Aug 25	-10.9%
Jul 25	-7.42%
Jul 25	-13.46%
Jul 25	-14.61%
Jul 25	-14.96%
Jun 25	-16.15%
Jun 25	-14.79%
Jun 25	-16.44%
Jun 25	-21.08%
May 25	-15.74%
May 25	-14.01%
May 25	-12.81%
May 25	-11.85%
May 25	-11.6%
Apr 25	-12.34%
Apr 25	-10.11%
Apr 25	-9.91%
Apr 25	-10.81%
Mar 25	-11.01%
Mar 25	-11.07%
Mar 25	-10.29%
Mar 25	-12.17%
Feb 25	-12.09%
Feb 25	-128.02%
Feb 25	-11.94%
Feb 25	-10.73%
Jan 25	-11.93%
Jan 25	-12.01%
Jan 25	-10.87%
Jan 25	-10.92%
Jan 25	-11.52%
Dec 24	-12.63%
Dec 24	-10.66%
Dec 24	-14.11%
Dec 24	-15.24%
Nov 24	-16.07%
Nov 24	-38.71%
Nov 24	-34.29%
Nov 24	-36.02%
Nov 24	-35.13%
Oct 24	-32.67%

Price to Sales

LOBEF Price to Sales by year
Period	Price to Sales
May 25	64.01
May 25	70
May 25	75.67
May 25	77.28
Apr 25	72.64
Apr 25	88.68
Apr 25	90.49
Apr 25	82.91
Mar 25	81.41
Mar 25	80.96
Mar 25	87.1
Mar 25	73.66
Feb 25	74.16
Feb 25	1.77
Feb 25	18.95
Feb 25	21.09
Jan 25	18.96
Jan 25	18.83
Jan 25	20.82
Jan 25	20.73
Jan 25	19.64
Dec 24	17.92
Dec 24	21.22
Dec 24	16.03
Dec 24	14.85
Nov 24	14.08
Nov 24	2.65
Nov 24	3
Nov 24	2.85
Nov 24	2.92
Oct 24	3.14
Oct 24	3.2
Oct 24	3.14
Oct 24	3.13
Sep 24	3.08
Sep 24	2.58
Sep 24	2.39
Sep 24	3.2
Aug 24	3.24
Aug 24	1.54
Aug 24	1.55
Aug 24	1.59
Aug 24	1.55
Jul 24	1.57
Jul 24	1.36
Jul 24	1.57
Jul 24	1.65
Jun 24	1.52
Jun 24	1.3
Jun 24	1.56
Jun 24	1.7
May 24	1.75
May 24	1.72
May 24	1.6
May 24	1.72
May 24	1.72
Apr 24	1.66
Apr 24	1.69
Apr 24	1.35
Apr 24	1.32
Mar 24	1.59
Mar 24	1.62
Mar 24	1.59
Mar 24	1.97
Mar 24	1.92
Feb 24	2.98
Feb 24	3.44
Feb 24	0.34
Feb 24	3.35
Jan 24	3.44
Jan 24	3.97
Jan 24	3.42
Jan 24	3.73
Dec 23	2.54
Dec 23	2.75
Dec 23	2.78
Dec 23	3.63
Dec 23	3.23

Price to Book

LOBEF Price to Book by year
Period	Price to Book
Sep 26	6.4
Sep 26	7
Sep 26	7.16
Aug 26	12.5
Aug 26	12.66
Aug 26	10.54
Aug 26	11.57
Jul 26	11.06
Jul 26	14.76
Jul 26	13.6
Jul 26	15.94
Jul 26	15.13
Jun 26	13.37
Jun 26	13.22
Jun 26	16.41
Jun 26	16.29
May 26	15.32
May 26	8.86
May 26	9.93
May 26	10.23
May 26	8.72
Apr 26	9.06
Apr 26	5.8
Apr 26	5.23
Apr 26	5.07
Mar 26	5.64
Mar 26	4.84
Mar 26	4.89
Mar 26	0.44
Feb 26	2.81
Feb 26	2.97
Feb 26	2.24
Feb 26	2.58
Jan 26	2.79
Jan 26	2.39
Jan 26	3.31
Jan 26	3
Jan 26	2.25
Dec 25	2.11
Dec 25	2.07
Dec 25	1.96
Dec 25	1.85
Nov 25	0.28
Nov 25	1.79
Nov 25	2.39
Nov 25	0.24
Oct 25	2.7
Oct 25	2.49
Oct 25	2.39
Oct 25	2.95
Oct 25	2.98
Sep 25	2.9
Sep 25	2.94
Sep 25	2.69
Sep 25	2.95
Aug 25	2.89
Nov 23	1.89
Nov 23	1.48
Nov 23	1.66
Nov 23	1.72
Oct 23	1.28
Oct 23	1.84
Oct 23	1.85
Oct 23	1.52
Sep 23	2.35
Sep 23	2.05
Sep 23	1.8
Sep 23	1.74
Sep 23	2.14

No video analysis for this stock yet. Request one from our team.

News: LOBEF

accessnewswire.com · 14 Sep 2026

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16 ● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses ● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd.

newsfilecorp.com · 14 Sep 2026

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in the upcoming 3 rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel.

accessnewswire.com · 31 Aug 2026

Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce closing of the second tranche of its previously announced non-brokered private placement offering of common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share (the "Private Placement").

accessnewswire.com · 28 Aug 2026

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd.

accessnewswire.com · 28 Aug 2026

Lobe Sciences Expands Leadership Team with New CFO Appointment

Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing differentiated therapeutics for serious conditions with significant unmet medical needs, today announced the appointment of Dr. David Kideckel, Ph.D.

accessnewswire.com · 20 Aug 2026

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd.

accessnewswire.com · 18 Aug 2026

Lobe Sciences Reports Third Quarter 2026 Financial Results

VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced its unaudited interim financial results for the third quarter of fiscal 2026 ended May 31, 2026 ("Q3 2026").

accessnewswire.com · 12 Aug 2026

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd.